Adobe Systems Inc. Message Board

there are 17,000 contracts for 7 in jan going for 15 cents. That translates into 1,700,000 shares for the stock to double in 7 months. Lot's of upside pressure.

let's put our thinking caps on this drug is the same as Wellbutrin and Zyban and is available as a generic. If my doc recommended this at a higher cost than generic I would find another doc!

That is just the point it seems like they have some insight into novel drug therapy but other issues are keeping them from taking off. Management issue +assets = takeover target.

I think 5 at years end is reasonable and so do analyst Short term isn't a good idea for this stock

I once owned a follow number of shares, I look at this from time o time to remind myself tat END and ENron were both in Houston and cost me more than a lifetime supply of gasoline

You will have to wait, I think this stock goes on what people think it is going to be worth, cash position and recent sales confirm it will be around to profit from it's drugs. UCB has warrants for 1,000,000 shares at $8 which I suspect we will reach next year. There is a possibility that one of their drugs will get early approval if it is shown to work in with lupus nephritis or brain disease because these are life threatening and there are not good alternatives.

Sentiment: Strong Buy

Please see above discussion I think I just found an envelop for an "Oscar for the fastest appreciating biotech company for 2113" and looked inside,
This company has had a number of false starts but I wouldn't sell at 2.70, or 5. I would sell 10% at $24. Which is very likely by 2015

OMG There is intelligent life on this board!

Tell me where I find the Silicon Investors moderated IMMU board.

Your explanation makes sense. I thought the initial phase 3 studies were underfunded.
I understand UCB is a very conservative company. Of the three drugs used to treat IBD both infliximab and adalimumab have indications for Crohn’s and ulcerative colitis but UCB’s certolizumab is indicated only for Crohn’s. To my knowledge they haven’t committed to seeking an indication for CUC. I think UCB is extremely intelligent but very cautious looking at the total cost, risk and return in these expensive studies.

All of this makes me think epratuzumab is a very promising drug. Response rates of are not that much different than the response rates to TNF alpha antibodies mentioned above and they are billion dollar drugs. It looks like Epratuzumab is going to be at least twice as effective as Benlysta.
Furthermore the preliminary data looks promising in lupus cerebritis and nephritis. Given the morbidity and mortality of these two lupus complications, FDA approval may occur before completion of phase 3 trials!

It sounds like you have knowledge of this drug. But I came across IMMU when I was looking for a way to use microRNA expression in an effort to link diet with disease. If we could predict tissue injury from food in a prospective fashion we would see increasing response rates to any treatment even placebo!
I think that makes sense. Anyway thanks for the info. If you are interested in exploring epitopes and disease further please email me.
same name at yahoo mail

Sentiment: Strong Buy

the study was in Br J Clin Pharmacol. 2011 February; 71(2): 175–182.

Thanks,

Your concerns bother me. Is the original team gone? Is there a new team trying to push the company forward?
Small biotechs like this fail frequently if they try to develop and market drugs without help.
Currently the have two multibillion partners maybe more. I am very familiar with the companies they are working with and they have some very smart people involved.
All I am saying is that IMMU has good partnerships. But is this enough?

I thought I would never get them out of the house thanks

I send report to my imaginary friends. LOL